Organon Files 8-K on Financial Results and Disclosures

Ticker: OGN · Form: 8-K · Filed: Feb 15, 2024 · CIK: 1821825

Organon & CO. 8-K Filing Summary
FieldDetail
CompanyOrganon & CO. (OGN)
Form Type8-K
Filed DateFeb 15, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-disclosure, regulatory-filing, results-of-operations

TL;DR

**Organon just filed a standard 8-K reporting financial results and other disclosures, but the specific details aren't in this snippet!**

AI Summary

Organon & Co. filed an 8-K on February 15, 2024, to disclose its results of operations and financial condition. The filing also included Regulation FD disclosures and financial statements and exhibits, indicating the company's routine update on its financial status. The document, with CIK 0001821825, was filed from its business address at 30 Hudson Street, Floor 33, Jersey City, NJ 07302.

Why It Matters

This filing signals Organon & Co.'s commitment to financial transparency, providing investors with updated information on its performance and condition. Such disclosures are vital for market analysis and investor decision-making.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial results and other information, not an event that inherently carries high risk based on the provided snippet.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by Organon & Co.?

The 8-K filing by Organon & Co. is to report on Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits.

When was this 8-K filed?

The 8-K was filed on February 15, 2024.

What is Organon & Co.'s Central Index Key (CIK)?

Organon & Co.'s Central Index Key (CIK) is 0001821825.

Where is Organon & Co.'s principal executive office located?

Organon & Co.'s principal executive office is located at 30 Hudson Street, Floor 33, Jersey City, NJ 07302.

What is Organon & Co.'s Standard Industrial Classification (SIC)?

Organon & Co.'s Standard Industrial Classification (SIC) is PHARMACEUTICAL PREPARATIONS [2834].

Filing Stats: 751 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2024-02-15 07:48:45

Key Financial Figures

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition. On February 15, 2024, Organon & Co. (the " Company ") issued a press release (the " Earnings Release ") regarding its results for the quarter and full year ended December 31, 2023. The Earnings Release is included as Exhibit 99.1 to this report. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is considered to be "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to liability under that Section. The information in this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended (the " Securities Act ") or the Exchange Act, except as shall be expressly set forth by specific reference in such filing or document. The release contains forward-looking statements regarding the Company and includes a cautionary statement identifying important factors that could cause actual results to differ materially from those anticipated.

01

Item 7.01 Regulation FD Disclosure. In connection with the conference call announced in the Earnings Release, on February 15, 2024, the Company made available the Company Information Presentation relating to its financial results for the quarter and full year ended December 31, 2023. The Company Information Presentation may be accessed within the investor relations section of the Company's website, https://www.organon.com. A copy of the Company Information Presentation is attached hereto as Exhibit 99.2 and is incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.2 attached hereto, is considered to be "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to liability under that Section. The information in this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing or document. The Company Information Presentation contains forward-looking statements regarding the Company and includes a cautionary statement identifying important factors that could cause actual results to differ materially from those anticipated.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated February 15, 2024, relating to results of operations and financial condition. 99.2 Company Information Presentation. 104 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Organon & Co. By: /s/ Matthew Walsh Name: Matthew Walsh Title: Chief Financial Officer Dated: February 15, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing